Analysis of clinical features of Mycobacterium intracellulare pulmonary disease and Mycobacterium kansas pulmonary disease

doi:10.3969/j.issn.2096-8493.20210049

Abstract

Abstract:

The clinical data (including sex, age, smoking history, lymphocyte subsets, and comorbidity of pulmonary diseases, immune system diseases and diseases of other systems) of 168 cases of Mycobacterium intracellulare pulmonary disease (intracellulare group) and 90 cases of Mycobacterium kansas pulmonary disease (kansas group) diagnosed in the Fifth People’s Hospital of Suzhou from March 2014 to April 2021 were analyzed. As it turned out, the intracellulare group patients were of significant differences from the Kansas group in a number of figures (the intracellulare group: male (47.62% (80/168)), average age ((62.23±1.01) years old), smoking history (5.36% (9/168)), complicated with pulmonary diseases (58.93% (99/168)), complicated with hypertension (15.48% (26/168)), complicated with diseases of other systems (20.83% (35/168)), the expression rates of CD4 ⁺T lymphocytes ((34.82±0.73) %) and NK cells ((21.26±0.94) %); the Kansas group: (91.11% (82/90), (45.82±1.58) years old, 18.89% (17/90), 26.67% (24/90),5.56% (5/90), 10.00% (9/90), (38.66±1.03) %, (16.55±1.07) %), (χ²=47.447, P=0.000; t=4.145, P=0.000; χ ²=11.842, P=0.001; χ ²=24.452, P=0.000; χ ²=5.456, P=0.020; χ ²=4.862, P=0.027; t=-3.058, P=0.003; t=3.117, P=0.002)). The clinical characteristics of Mycobacterium intracellulare pulmonary disease and Mycobacterium kansas pulmonary disease are different in sex, age, complicated diseases, and lymphocyte subsets, which has certain reference value for the clinical differential diagnosis of those two diseases.

Key words: Lung diseases, Mycobacterium intracellulare, Mycobacterium kansasii, Disease attributes, Comparative study

YAN Jin-yu, ZOU Tao, GUO Jian, XU Yong, TANG Pei-jun, FENG Yan-jun. Analysis of clinical features of Mycobacterium intracellulare pulmonary disease and Mycobacterium kansas pulmonary disease[J]. Journal of Tuberculosis and Lung Disease , 2021, 2(3): 294-297. doi: 10.3969/j.issn.2096-8493.20210049

Figures/Tables 2

临床特征	胞内组(168例)	堪萨斯组(90例)	统计检验值	P值
吸烟[例(发生率,%)]	9(5.36)	17(18.89)	χ²=11.842	0.001
并发肺部基础疾病[例(发生率,%)]	99(58.93)	24(26.67)	χ²=24.452	0.000
肺气肿	28(16.67)	6(6.67)	χ²=5.122	0.024
慢性阻塞性肺疾病	24(14.29)	4(4.44)	χ²=4.894	0.027
肺结核	48(28.57)	9(10.00)	χ²=11.743	0.001
支气管扩张	55(32.74)	5(5.56)	χ²=24.262	0.000
肺纤维化	7(4.17)	0(0.00)	χ²=2.438	0.118
其他	21(12.50)	3(3.33)	χ²=5.837	0.016
并发免疫系统疾病[例(发生率,%)]	4(2.38)	3(3.33)	χ²=0.002	0.963
强制性脊柱炎	1(0.60)	1(1.11)	χ²=0.000	1.000
类风湿性关节炎	1(0.60)	1(1.11)	χ²=0.000	1.000
其他	2(1.19)	1(1.11)	χ²=0.000	1.000
糖皮质激素使用史[例(发生率,%)]	1(0.60)	2(2.22)	χ²=0.305	0.581
并发全身性基础疾病史[例(发生率,%)]	35(20.83)	8(8.89)	χ²=6.020	0.014
高血压	26(15.48)	5(5.56)	χ²=5.456	0.020
糖尿病	9(5.36)	3(3.33)	χ²=0.181	0.670
并发其他系统疾病[例(发生率,%)]	35(20.83)	9(10.00)	χ²=4.862	0.027
淋巴细胞亚群表达率(%, $x ¯$ ±s)
CD4⁺T淋巴细胞	34.82±0.73	38.66±1.03	t=-3.058	0.003
CD8⁺T淋巴细胞	25.82±0.72	26.98±1.14	t=-0.897	0.371
B淋巴细胞	11.96±0.50	11.73±0.57	t=0.285	0.776
NK细胞	21.26±0.94	16.55±1.07	t=3.117	0.002

References 15

[1]	Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol, 2020, 18(7):392-407. doi: 10.1038/s41579-020-0331-1. doi: 10.1038/s41579-020-0331-1 pmid: 32086501
[2]	Furuuchi K, Morimoto K, Yoshiyama T, et al. Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan. Respir Med, 2019, 152:74-80. doi: 10.1016/j.rmed.2019.05.001. doi: S0954-6111(19)30153-2 pmid: 31128614
[3]	周洪经, 吴敏, 郭明日, 等. 2018—2019年天津地区非结核分枝杆菌菌种分布及耐药性观察. 山东医药, 2021, 61(9):77-79. doi: 10.3969/j.issn.1002-266X.2021.09.020. doi: 10.3969/j.issn.1002-266X.2021.09.020
[4]	朱业蕾, 潘爱珍, 周琳, 等. 浙江省非结核分枝杆菌流行状况及耐药性分析. 预防医学, 2021, 33(1):6-10. doi: 10.19485/j.cnki.issn2096-5087.2021.01.002. doi: 10.19485/j.cnki.issn2096-5087.2021.01.002
[5]	Donohue MJ. Epidemiological risk factors and the geographical distribution of eight Mycobacterium species. BMC Infect Dis, 2021, 21(1):258. doi: 10.1186/s12879-021-05925-y. doi: 10.1186/s12879-021-05925-y pmid: 33706712
[6]	Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis, 2014, 6(3):210-20. doi: 10.3978/j.issn.2072-1439.2013.12.24. doi: 10.3978/j.issn.2072-1439.2013.12.24
[7]	中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 非结核分枝杆菌病诊断与治疗专家共识. 中华结核和呼吸杂志, 2012, 35(8):572-580.
[8]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11):918-946. doi: 10.3760/cma.j.cn112147-20200508-00570. doi: 10.3760/cma.j.cn112147-20200508-00570
[9]	王黎霞. 分枝杆菌分离培养标准化操作程序及质量保证手册. 北京: 人民卫生出版社, 2013: 3.
[10]	张洁, 苏建荣, 丁北川, 等. 北京地区非结核分枝杆菌菌种分布及耐药性研究. 中华结核和呼吸杂志, 2017, 40(3):210-214. doi: 10.3760/cma.j.issn.1001-0939.2017.03.013. doi: 10.3760/cma.j.issn.1001-0939.2017.03.013
[11]	Tan Y, Deng Y, Yan X, et al. Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study. J Infect, 2021: S0163-4453(21)00261-9. doi: 10.1016/j.jinf.2021.05.019. doi: 10.1016/j.jinf.2021.05.019
[12]	Feng JY, Chen WC, Chen YY, et al. Clinical relevance and diagnosis of nontuberculous mycobacterial pulmonary disease in populations at risk. J Formos Med Assoc, 2020, 119Suppl 1:S23-S31. doi: 10.1016/j.jfma.2020.05.012. doi: 10.1016/j.jfma.2020.05.012 URL
[13]	Liu VX, Winthrop KL, Lu Y, et al. Association between inhaled corticosteroid use and pulmonary nontuberculous mycobacterial infection. Ann Am Thorac Soc, 2018, 15(10):1169-1176. doi: 10.1513/AnnalsATS.201804-245OC. doi: 10.1513/AnnalsATS.201804-245OC URL
[14]	Abe Y, Fukushima K, Hosono Y, et al. Host Immune Response and Novel Diagnostic Approach to NTM Infections. Int J Mol Sci, 2020, 21(12):4351. doi: 10.3390/ijms21124351. doi: 10.3390/ijms21124351 URL
[15]	宋华峰, 赵静, 陈慧, 等. 非结核分枝杆菌感染患者外周血免疫细胞改变及其临床意义. 国家免疫学杂志, 2020, 43(1):7-14. doi: 10.3760/cma.j.issn.1673-4394.2020.01.002. doi: 10.3760/cma.j.issn.1673-4394.2020.01.002

年龄组 (岁)	胞内组						堪萨斯组
	男性		女性		合计		男性		女性		合计
	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	构成比 (%)
15~29	2	2.50	0	0.00	2	1.19	7	8.54	1	12.50	8	8.89
30~44	5	6.25	12	13.64	17	10.12	33	40.24	4	50.00	37	41.11
45~59	11	13.75	20	22.73	31	18.45	27	32.93	2	25.00	29	32.22
60~74	45	56.25	48	54.54	93	55.36	9	10.97	1	12.50	10	11.11
≥75	17	21.25	8	9.09	25	14.88	6	7.32	0	0.00	6	6.67
合计	80	100.00	88	100.00	168	100.00	82	100.00	8	100.00	90	100.00